A phase IIb study of adalimumab to treat patients with Dupuytren’s disease has delivered positive data, suggesting that a local injection of the drug in the early stages of fibrosis could have a profound biological effect and provide a much-needed therapeutic option for patients.
180 Life Sciences Adalimumab Study Publishes Positive IIb Dupuytren’s Disease Data
Company Has Started Initial Consultations With US And UK Regulators
Adalimumab could find itself with a tenth official indication, after 180 Life Sciences found that it was able to effectively treat nodule hardness and size in Dupuytren’s disease during a phase IIb study.
